nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.07.2007 | Original Paper

Non-Hodgkin lymphoma with t(14;18): clonal evolution patterns and cytogenetic–pathologic–clinical correlations

verfasst von: Hege Vangstein Aamot, Emina Emilia Torlakovic, Marianne Brodtkorb Eide, Harald Holte, Sverre Heim

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 7/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The pattern and frequency of secondary chromosome abnormalities in t(14;18)-carrying non-Hodgkin lymphomas (NHL) were evaluated for differences in relation to histologic NHL subtype and patients’ outcome.

Methods

One hundred and forty-nine NHL patients with t(14;18) and complete cytogenetic, morphologic, and clinical information were selected.

Results

One hundred and twelve cases were follicular lymphoma (FL) and 37 were diffuse large B-cell lymphoma (DLBCL). One hundred and forty cases showed secondary aberrations (94%, median = 6.0). The most frequent were losses from chromosome arms 1p and 6q and +7 (26%). Loss from 1q, +7, and +12 were more frequent in DLBCL than in FL. Loss from 1p, Xp, and −16 were more frequent in FL grade 3 than in FL grades 1 and 2. Patients with <6.0 secondary cytogenetic aberrations had better prognosis than did those with a higher number of aberrations. Trisomy 21 was associated with shorter patient survival. FLIPI score, the number of secondary chromosomal aberrations, and +21 were all of independent prognostic value in Cox multivariate analysis. FL grade 1-3a patients that had received chemotherapy, showed a higher frequency of i(6p) and loss from 6q.

Conclusion

Secondary chromosomal aberrations showed some correlation with the morphologic subgroups of t(14;18)-NHL. Trisomy 21 and the presence of >6.0 secondary cytogenetic aberrations both correlated with shorter overall survival.

Nur mit Berechtigung zugänglich

Aamot H, Micci F, Holte H, Delabie J, Heim S (2002) M-FISH cytogenetic analysis of non-Hodgkin lymphomas with t(14;18)(q32;q21) and add(1)(p36) as a secondary abnormality shows that the extra material often comes from chromosome arm 17q. Leuk Lymphoma 43:1051–1056PubMed

Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL, Korsmeyer SJ (1985) Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41:899–906PubMedCrossRef

Barrans SL, Evans PA, O’Connor SJ, Kendall SJ, Owen RG, Haynes AP, Morgan GJ, Jack AS (2003) The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res 9:2133–2139PubMed

Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontet C, Bryon PA, Coiffier B (1997) Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 15:1587–1594PubMed

Bernell P, Jacobsson B, Liliemark J, Hjalmar V, Arvidsson I, Hast R (1998) Gain of chromosome 7 marks the progression from indolent to aggressive follicle centre lymphoma and is a common finding in patients with diffuse large B-cell lymphoma: a study by FISH. Br J Haematol 101:487–491PubMedCrossRef

Boonstra R, Bosga-Bouwer A, Mastik M, Haralambieva E, Conradie J, van den BE, van den BA, Poppema S (2003) Identification of chromosomal copy number changes associated with transformation of follicular lymphoma to diffuse large B-cell lymphoma. Hum Pathol 34:915–923PubMedCrossRef

Bosga-Bouwer AG, van Imhoff GW, Boonstra R, van der Veen A, Haralambieva E, van den BA, de Jong B, Krause V, Palmer MC, Coupland R, Kluin PM, van den BE, Poppema S (2003) Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. Blood 101:1149–1154PubMedCrossRef

Cigudosa JC, Parsa NZ, Louie DC, Filippa DA, Jhanwar SC, Johansson B, Mitelman F, Chaganti RS (1999) Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas. Genes Chromosomes Cancer 25:123–133PubMedCrossRef

Davies AJ, Lee AM, Taylor C, Clear AJ, Goff LK, Iqbal S, Cuthbert-Heavens D, Calaminici M, Norton AJ, Lister TA, Fitzgibbon J (2005) A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. Leukemia 19:1459–1465PubMedCrossRef

Goodlad JR, Batstone PJ, Hamilton D, Hollowood K (2003) Follicular lymphoma with marginal zone differentiation: cytogenetic findings in support of a high-risk variant of follicular lymphoma. Histopathology 42:292–298PubMedCrossRef

Heim S, Mitelman F (1995) Cancer cytogenetics: chromosomal and molecular genetic aberrations of tumor cells. Wiley-Liss, New York

Höglund M, Sehn L, Connors JM, Gascoyne RD, Siebert R, Sall T, Mitelman F, Horsman DE (2004) Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer 39:195–204PubMedCrossRef

Horsman DE, Gascoyne RD, Coupland RW, Coldman AJ, Adomat SA (1995) Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t(14; 18) in follicular lymphoma. Am J Clin Pathol 103:472–478PubMed

Horsman DE, Connors JM, Pantzar T, Gascoyne RD (2001) Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes Chromosomes Cancer 30:375–382PubMedCrossRef

Hough RE, Goepel JR, Alcock HE, Hancock BW, Lorigan PC, Hammond DW (2001) Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma. Br J Cancer 84:499–503PubMedCrossRef

Iqbal J, Sanger WG, Horsman DE, Rosenwald A, Pickering DL, Dave B, Dave S, Xiao L, Cao K, Zhu Q, Sherman S, Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Ott G, Muller-Hermelink HK, Delabie J, Braziel RM, Jaffe ES, Campo E, Lynch JC, Connors JM, Vose JM, Armitage JO, Grogan TM, Staudt LM, Chan WC (2004) BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol 165:159–166PubMed

ISCN (2005) An international system for human cytogenetic nomenclature. Shaffer LG, Tommerup N (eds) S. Karger, Basel

Jaffe ES, Harris NL, Stein H et al (2001) Pathology and genetics of tumors of hematopoietic and lymphoid tissues. IARC Press, Lyon, France

Johansson B, Mertens F, Mitelman F (1995) Cytogenetic evolution patterns in non-Hodgkin’s lymphoma. Blood 86:3905–3914PubMed

Kimby E, Bjorkholm M, Gahrton G, Glimelius B, Hagberg H, Johansson B, Johansson H, Juliusson G, Jarnmark M, Lofvenberg E (1994) Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin’s lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 5(Suppl 2):67–71

Lestou VS, Gascoyne RD, Sehn L, Ludkovski O, Chhanabhai M, Klasa RJ, Husson H, Freedman AS, Connors JM, Horsman DE (2003) Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome. Br J Haematol 122:745–759PubMedCrossRef

Lossos IS, Levy R (2000) Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5’ noncoding regulatory region of the BCL-6 gene. Blood 96:635–639PubMed

Lossos IS, Levy R (2003) Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions. Semin Cancer Biol 13:191–202PubMedCrossRef

Lossos IS, Alizadeh AA, Diehn M, Warnke R, Thorstenson Y, Oefner PJ, Brown PO, Botstein D, Levy R (2002) Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci USA 99:8886–8891PubMedCrossRef

Mann RB, Berard CW (1983) Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method. Hematol Oncol 1:187–192PubMedCrossRef

Mitelman F, Johansson B, Mertens F (eds) (2006) Mitelman database of chromosome aberrations in cancer. May be accessed at: http://www.cgap.nci.nih.gov/Chromosomes

Mohamed AN, Palutke M, Eisenberg L, Al Katib A (2001) Chromosomal analyses of 52 cases of follicular lymphoma with t(14;18), including blastic/blastoid variant. Cancer Genet Cytogenet 126:45–51PubMedCrossRef

Nathwani BN, Anderson JR, Armitage JO, Cavalli F, Diebold J, Drachenberg MR, Harris NL, MacLennan KA, Muller-Hermelink HK, Ullrich FA, Weisenburger DD (1999) Clinical significance of follicular lymphoma with monocytoid B cells. Non-Hodgkin’s Lymphoma Classification Project. Hum Pathol 30:263–268PubMedCrossRef

Ott G, Katzenberger T, Lohr A, Kindelberger S, Rudiger T, Wilhelm M, Kalla J, Rosenwald A, Muller JG, Ott MM, Muller-Hermelink HK (2002) Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 99:3806–3812PubMedCrossRef

Pinyol M, Cobo F, Bea S, Jares P, Nayach I, Fernandez PL, Montserrat E, Cardesa A, Campo E (1998) p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin’s lymphomas. Blood 91:2977–2984PubMed

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937–1947PubMedCrossRef

Solal-Celigny P (2002) Increasing treatment options in indolent non-Hodgkin’s lymphoma. Semin Oncol 29:2–6PubMedCrossRef

Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haioun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E (2004) Follicular lymphoma international prognostic index. Blood 104:1258–1265PubMedCrossRef

Teixeira MR, Micci F, Dietrich CU, Heim S (2000) Detailed genome-wide screening for inter- and intrachromosomal abnormalities by sequential G-banding and RxFISH color banding of the same metaphase cells. Cancer Genet Cytogenet 119:94–101PubMedCrossRef

The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994

Tilly H, Rossi A, Stamatoullas A, Lenormand B, Bigorgne C, Kunlin A, Monconduit M, Bastard C (1994) Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 84:1043–1049PubMed

Torlakovic EE, Vangstein Aamot H, Heim S (2006) A marginal zone phenotype in follicular lymphomas with t(14;18) is associated with secondary cytogenetic aberrations typical of marginal zone lymphoma. J Pathol 209:258–264PubMedCrossRef

Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM (1984) Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226:1097–1099PubMedCrossRef

Tsujimoto Y, Cossman J, Jaffe E, Croce CM (1985) Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440–1443PubMedCrossRef

Weisenburger DD, Gascoyne RD, Bierman PJ, Shenkier T, Horsman DE, Lynch JC, Chan WC, Greiner TC, Connors JM, Vose JM, Armitage JO, Sanger WG (2000) Clinical significance of the t(14;18) and BCL2 overexpression in follicular large cell lymphoma. Leuk Lymphoma 36:513–523PubMedCrossRef

Younes A, Pugh W, Goodacre A, Katz R, Rodriguez MA, Hill D, Cabanillas F, Andreeff M (1994) Polysomy of chromosome 12 in 60 patients with non-Hodgkin’s lymphoma assessed by fluorescence in situ hybridization: differences between follicular and diffuse large cell lymphoma. Genes Chromosomes Cancer 9:161–167PubMedCrossRef

Yunis JJ, Oken MM, Kaplan ME, Ensrud KM, Howe RR, Theologides A (1982) Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin’s lymphoma. N Engl J Med 307:1231–1236PubMedCrossRef

Yunis JJ, Frizzera G, Oken MM, McKenna J, Theologides A, Arnesen M (1987) Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. N Engl J Med 316:79–84PubMedCrossRef

Titel: Non-Hodgkin lymphoma with t(14;18): clonal evolution patterns and cytogenetic–pathologic–clinical correlations
verfasst von: Hege Vangstein Aamot
Emina Emilia Torlakovic
Marianne Brodtkorb Eide
Harald Holte
Sverre Heim
Publikationsdatum: 01.07.2007
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 7/2007
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-006-0188-3

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Non-Hodgkin lymphoma with t(14;18): clonal evolution patterns and cytogenetic–pathologic–clinical correlations

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2007

Midkine as a prognostic marker for gastrointestinal stromal tumors

Transforming growth factor-β downregulates interleukin-2-induced phosphorylation of signal transducer and activator of transcription 5 in human renal cell carcinoma

Peritoneal lavage CEA/CA125 is a prognostic factor for gastric cancer patients

HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy

Diminished quality of life in patients with cancer correlates with tryptophan degradation

Continuing with letrozole offers greater benefits

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie